Shares of Medigene AG (ETR:MDG1 – Get Free Report) fell 13.2% during mid-day trading on Wednesday . The stock traded as low as €2.31 ($2.51) and last traded at €2.36 ($2.57). 171,348 shares were traded during trading, a decline of 44% from the average session volume of 306,207 shares. The stock had previously closed at €2.72 ($2.96).
Medigene Stock Down 13.2 %
The stock has a market capitalization of $57.96 million, a P/E ratio of -1.98, a P/E/G ratio of 7.12 and a beta of 0.79. The firm’s fifty day moving average is €1.58 and its 200-day moving average is €1.60. The company has a current ratio of 4.74, a quick ratio of 5.85 and a debt-to-equity ratio of 11.55.
Medigene Company Profile
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Read More
- Five stocks we like better than Medigene
- With Risk Tolerance, One Size Does Not Fit All
- Best Bear Market Funds: Top 3 Investment Options to Consider
- What does consumer price index measure?
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- How to Calculate Options Profits
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Medigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medigene and related companies with MarketBeat.com's FREE daily email newsletter.
